{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Samrat Pharmachem Ltd
Why is Samrat Pharmachem Ltd falling/rising?
On 12-Jan, Samrat Pharmachem Ltd’s stock price fell sharply by 3.15% to close at ₹215.05, marking a continuation of a downward trend amid persistent operational challenges and sustained underperformance relative to market benchmarks.
Samrat Pharmachem Ltd Falls to 52-Week Low of Rs.210 Amidst Continued Underperformance
Samrat Pharmachem Ltd’s stock declined sharply to a fresh 52-week low of Rs.210 on 12 Jan 2026, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical company’s shares have underperformed both the sector and broader market indices, reflecting persistent pressures on its financial and market performance.
Samrat Pharmachem Ltd Falls to 52-Week Low of Rs.222.05
Samrat Pharmachem Ltd’s stock declined to a fresh 52-week low of Rs.222.05 on 7 January 2026, marking a significant downturn amid persistent underperformance relative to its sector and benchmark indices. The pharmaceutical and biotechnology company’s shares have been trading below all key moving averages, reflecting ongoing pressures on its valuation and financial metrics.
Samrat Pharmachem Ltd is Rated Strong Sell
Samrat Pharmachem Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Samrat Pharmachem Ltd Stock Falls to 52-Week Low of Rs.224.95
Samrat Pharmachem Ltd’s stock declined to a fresh 52-week low of Rs.224.95 on 29 Dec 2025, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and benchmark indices, reflecting persistent pressures on its financial and market performance.
Samrat Pharmachem Ltd is Rated Strong Sell
Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 August 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook.
Samrat Pharmachem Falls to 52-Week Low of Rs.230.05 Amidst Prolonged Downtrend
Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.230.05 today, marking a significant decline amid a sustained downward trend. The stock has experienced a series of losses over the past four trading sessions, culminating in a cumulative return of -9.65% during this period, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Samrat Pharmachem Falls to 52-Week Low of Rs.237 Amidst Continued Downtrend
Samrat Pharmachem's stock price reached a fresh 52-week low of Rs.237 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced its performance over the past year.
Samrat Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions
Samrat Pharma, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing operational and financial challenges. This shift highlights the company’s current standing amid a difficult market environment and evolving investor perspectives.
Samrat Pharmachem Stock Falls to 52-Week Low of Rs.250
Samrat Pharmachem's shares reached a fresh 52-week low of Rs.250 today, marking a significant decline amid broader market gains. The stock underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space.
Samrat Pharmachem Stock Falls to 52-Week Low of Rs.251 Amidst Prolonged Underperformance
Samrat Pharmachem’s shares touched a fresh 52-week low of Rs.251 today, marking a significant price level amid a year of sustained underperformance relative to the broader market and sector peers.
Samrat Pharmachem Falls to 52-Week Low of Rs.265 Amidst Continued Downtrend
Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.265 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.
Samrat Pharmachem Stock Falls to 52-Week Low of Rs.266.1 Amidst Continued Downtrend
Samrat Pharmachem has reached a new 52-week low of Rs.266.1 today, marking a significant decline in its stock price amid a broader market rally. The pharmaceutical company’s shares have slipped below all major moving averages, reflecting persistent pressures on its valuation and performance over the past year.
Is Samrat Pharma overvalued or undervalued?
As of November 18, 2025, Samrat Pharma is considered overvalued with a PE Ratio of 53.48, significantly higher than its peers, and has experienced a poor year-to-date return of -29.33%, indicating a shift in market perception from very attractive to very expensive.
Is Samrat Pharma overvalued or undervalued?
As of November 17, 2025, Samrat Pharma's valuation has improved to very attractive, indicating it is undervalued with a PE ratio of 53.08 and favorable metrics compared to competitors, despite a recent year-to-date return of -29.85% against the Sensex, while maintaining a strong long-term outlook with a 5-year return of 138.54%.
How has been the historical performance of Samrat Pharma?
Samrat Pharma's historical performance shows fluctuating financial metrics, with net sales rising from INR 137.45 crore in March 2020 to a peak of INR 310.65 crore in March 2023, followed by a decline and slight recovery. Key indicators like operating profit and profit after tax also experienced significant volatility during this period.
Samrat Pharmachem Stock Plummets to 52-Week Low of Rs. 266.55
Samrat Pharmachem has reached a new 52-week low, reflecting ongoing challenges in the market. The company's stock has declined significantly over the past year, underperforming compared to the broader market. Despite a historical growth in operating profits, recent financial results indicate a notable decrease in profitability.
How has been the historical performance of Samrat Pharma?
Samrat Pharma's historical performance indicates fluctuating profitability despite growth in net sales and total assets, with net sales rising from INR 137.45 crore in March 2020 to INR 285.86 crore in March 2025, but profit metrics declining significantly in recent years. Operating cash flow turned negative in March 2025, contrasting with previous positive trends.
Samrat Pharmachem Hits New 52-Week Low at Rs. 270.3
Samrat Pharmachem has reached a 52-week low, reflecting a significant decline in its stock price over the past year. The company has underperformed its sector and is trading below key moving averages. However, it maintains a positive return on capital employed and has seen increased foreign institutional investment.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
